For example,
Abrysvo vaccine monoclonal antibodies:
VRS in children: three drugs are marketed and reimbursed for the 2025-2026 season.CIPhotos / iStock / Getty Images Plus / via Getty Images
La Directorate General of Health (DGS) detailed the calendar and the options available in France for the 2025-2026 campaign of newborns and infants against syncytial respiratory virus infections (VRS) [1].
A campaign in three dates on the national territory – Abrysvo vaccine monoclonal antibodies
The start of this third campaign is planned for three different dates:
- 1is August 2025: Guyana
- 1is September 2025: Metropolitan France, Reunion, Martinique, Guadeloupe, Saint-Martin and Saint-Barthélemy
- 1is October 2025: Mayotte
Abrysvo vaccine or monoclonal antibodies – Abrysvo vaccine monoclonal antibodies
For this 2025-2026 season, three drugs are abrysvo vaccine monoclonal antibodies marketed and reimbursed by health insurance:
Beyfortus and Abrysvo are available in town.
Synagis, Beyfortus and Abrysvo are available in health establishments and registered on the list of specialties approved for communities.
These specialties will be made available in the city. In addition, in health establishments via Classic supply circuits and according to the campaign starting calendar.
The date of support for these treatments coincides with the start-up calendars of the 2025-2026 immunization campaign.
Protection of children exposed to their first VRS traffic season
The children exhibited at their first VRS traffic season are:
- children to be born from the start of the campaign;
- And as a catch -up, children born between February and August 2025.

.
For children who will be born From the start of the campaignthe two possible strategies are:
- Maternal vaccination against VRS with Abrysvo: it is to abrysvo vaccine monoclonal antibodies be achieved in pregnant women between 32e et 36e Amenorrhea week from the date of the start of the campaign. The immunization efficiency of this vaccine is observed from 2 weeks after injection and Up to 6 month after childbirth.
- If birth occurs within less than 14 days after vaccination or in the event of premature birth, catching up with Beyfortus is recommended [2] ;
- OR the immunization of the infant by Beyfortus or Synagis, provided that the mother was not vaccinated by Abrysvo in order to avoid double immunizations.
.
- In the event of a new pregnancy in a woman previously vaccinated against VRS infections during an earlier pregnancy, it is recommended to favor the administration of monoclonal antibodies in newborns from birth or infant [2].

. Additionally,
For born children Before the start of the campaign (Between February and August 2025), only the abrysvo vaccine monoclonal antibodies strategy based on the injection of monoclonal antibodies is possible.
Protection of children exposed to a second traffic season, vulnerable to a VRS infection
Children up to 24 months, exposed to their second VRS traffic season, but who remain vulnerable to an infection of this virus, can benefit from an immunization by Beyfortus or Synagis.
The DGS stresses that Beyfortus is not yet subject to care in this indication. but ensures that a request is underway. This care will only be effective after the publication of the decree dedicated to Official Journal.
Further reading: The heat wave is not dangerous that for the heart, it also promotes this infection – “Babies ozempic” and contraception: a British warning raises concerns – Pulmonary disease: metagenomic sequencing allows its early detection – A fourth uterus transplant successfully carried out in France – Liberation – This error kills 8 seniors out of 10 during heat blows.
